Company Quick10K Filing
IASO BioMed
10-Q 2019-09-30 Filed 2019-11-19
10-Q 2019-06-30 Filed 2019-08-19
10-Q 2019-03-31 Filed 2019-05-17
10-K 2018-12-31 Filed 2019-04-24
10-Q 2018-09-30 Filed 2018-11-19
10-Q 2018-06-30 Filed 2018-08-14
10-Q 2018-03-31 Filed 2018-05-15
10-K 2017-12-31 Filed 2018-04-16
10-Q 2017-09-30 Filed 2017-11-17
10-Q 2017-06-30 Filed 2017-08-21
10-Q 2017-03-31 Filed 2017-05-24
8-K 2019-09-17 Enter Agreement, Exhibits
8-K 2019-01-05 Enter Agreement, Exhibits
8-K 2018-11-01 Other Events, Exhibits
8-K 2018-08-20 Other Events, Exhibits
8-K 2018-03-05 Accountant, Exhibits
8-K 2018-03-01 Enter Agreement, Exhibits

IASO BioMed Financials

IASO Metrics, Comps, Filings

Quarterly | Annual

Business

We are a developmental stage biotechnology company focusing on researching and developing drugs and diagnostic tests for products with a large commercial market potential as well as drugs which may qualify to treat rare diseases. We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”) and will therefore be subject to reduced public company reporting requirements.

We are developing a peptide as a testosterone replacement therapy by stimulating the body's own production of testosterone rather than using synthetic steroid hormones. We believe that our peptide may be a safer alternative - to be proven after clinical studies - to currently available interventions for restoring testosterone levels in males. A second program of the company is a test for dementia which we believe will be the basis for developing an early stage blood or fluid test for Alzheimer's disease and other similar conditions. Based on the advice of our Scientific Advisory Board (SAB) and a meeting held on November 7, 2018, management has decided to focus the R&D efforts of the company on the peptide development whereas the dementia test remains an asset of the company which we will be seeking to out-license to a 3rd party for further development and commercialization.

A major part of our research and development activities was contracted out to the Research Institute of the McGill University Health Centre in Montreal Canada. The research team was led by Dr. Vassilios Papadopoulos, one of our founders and directors, who specializes in the biochemistry of steroids and their impact on human disease and use as biomarkers for detection of disease and who also serves as Chairman of our SAB. His research provides the foundation for our initial technologies and products. Dr Papadopoulos is currently the Dean of School of Pharmacy at USC.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Yacht Finders (YTFD) 0.0 0 927 0 0 -68 -68 -0
Zayo Group (ZGL) 49% 4.8 1% 9,881,100 8,522,500 2,575,500 1,250,000 145,800 1,166,700 5,606,600
Anterix (ATEX) -49% 4.9 -12% 282,901 20,419 3,679 -1,814 -35,001 -31,870 -157,494
BiomX (PHGE) -0.3 0% 71,207 751 0 0 56 361 -97
AGBA Acquisition (AGBA) 3.6 -1% 47,418 1,544 0 0 -262 -262 -949
Spanish Broadcasting System (SBSAA) 0% -0.9 -1% 455,176 540,592 125,994 0 -6,046 19,991 -18,924
US VR Global.com (USVR) 0.0 -586% 467 2,452 0 0 -2,737 -2,686 -103
NorthStar Healthcare (NSHI) 39% -65.4 -6% 2,173,018 1,479,658 220,271 85,058 -128,038 -21,567 1,411,109
Renewable Energy & Power (REAP) 3% -0.0 63% 2,124 3,156 617 17 1,340 1,282 -0
Cancer Capital (CNCL) 0.0 -9,752% 0 295 0 0 -23 -18 -0
Replay Acquisition (RPLA) -0.5 1% 292,543 9,270 0 0 3,076 3,076 -1,619
Joway Health Industries (GTVI) 53% 0.2 -20% 4,632 1,384 469 247 -904 -582 -91
Mission Broadcasting (MBCC) 0% 102.5 -4% 211,918 241,607 81,374 0 -8,552 2,148 220,200
IASO BioMed (IASO) 0.0 -11,174% 6 1,123 0 0 -716 -716 -3
SusGlobal Energy (SUSG) 22% -3.4 -43% 5,192 8,061 1,026 221 -2,212 -1,494 5,013
Puget Energy (PSD) 0% 0.3 0% 14,366,757 10,483,927 2,412,776 0 59,759 547,049 169,874
Graphic Packaging International (GPIL) 17% 3.5 5% 7,184,200 4,391,900 6,148,000 1,051,400 358,500 815,000 2,886,300
Ridgefield Acquisition (RDGA) 0.0 -5,559% 1 260 0 0 -44 -44 -1
Sirrus (SRUP) 67% -0.2 -2,185% 68 1,881 52 35 -1,492 -1,348 287
Reign Sapphire (RSAP) 75% -11.5 -26% 763 4,680 138 104 -201 -155 1,771

Balance Sheet ($'000)2017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash43233420582617814078113
Accounts Receivable
Inventory
PP&E
Assets46273722583118114278166
Accounts Payable19493133151204
Long-Term Debt
Liabilities2382922673144456135997448699731,123
Stockholders' Equity-192-265-230-292-387-583-418-603-791-958-1,116
Income Statement ($'000)2017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue0000000000
Cost of Revenue
Gross Profit
R&D140111191075103500
SG&A204122114104626120187138151343
Tax
Net Income-344-134-126-113-637-196-198-191-167-359
Cash Flow ($'000)2017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-24-51-118-69-66-32-156-65-67-17
Cash Investing
Cash Financing5430130551040308309